GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel
According to
This Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study is planning to enroll at least 350 individuals with sickle cell disease, aged six and older who are hospitalized for a vaso-occlusive crisis, and will evaluate the efficacy and safety of treatment with rivipansel. Trial participants must be receiving treatment with intravenous opioids for their vaso-occlusive crisis and must be able to receive the first dose of study drug within 24 hours of initiation of intravenous opioid therapy. The primary endpoint for the study will be time to readiness-for-discharge. Key secondary endpoints will include time to discharge, cumulative IV opioid consumption and time to discontinuation of IV opioids. For additional information about the RESET Trial and to learn more about eligibility, patients can visit www.resetsicklecell.com.
In
In 2011,
Rivipansel has previously received both Orphan Drug and Fast Track
status for the treatment of VOC from the FDA, and Orphan Product status
in the
About Sickle Cell Disease and VOC
Sickle cell disease is a genetic disease affecting 90,000 to 100,000
people in
About
GlycoMimetics is a clinical stage biotechnology company focused on the
discovery and development of novel glycomimetic drugs to address unmet
medical needs resulting from diseases in which carbohydrate biology
plays a key role.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding the
clinical development of rivipansel, including the recently initiated
Phase 3 clinical trial. Actual results may differ materially from those
in these forward-looking statements. For a further description of the
risks associated with these statements, as well as other risks facing
View source version on businesswire.com: http://www.businesswire.com/news/home/20150623006403/en/
Investor Contact:
sannes@annesassociates.com
or
Media
Contact:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media